SHSE:600276's Gross Margin % is ranked better than 96.58% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs SHSE:600276: 86.54
Jiangsu Hengrui Pharmaceuticals Co had a gross margin of 86.60% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jiangsu Hengrui Pharmaceuticals Co had a gross margin of 86.60% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jiangsu Hengrui Pharmaceuticals Co Gross Margin % Related Terms
Jiangsu Hengrui Pharmaceuticals Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Gross Margin % Chart
SHSE:600276 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Gross Margin % of 86.60% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is near median its historical median of 86.43. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Gross Margin % has ranged from 83.61 to 87.93. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #32 out of 935 companies in the Drug Manufacturers industry, placing it in the top 3.4%.
Is Jiangsu Hengrui Pharmaceuticals Co's Gross Margin % too high?
Jiangsu Hengrui Pharmaceuticals Co's current Gross Margin % of 86.60% is near median its 10-year median of 86.43. Over the past 10 years, this metric has ranged from a low of 83.61 to a high of 87.93. The Drug Manufacturers industry median Gross Margin % is 48.46. Jiangsu Hengrui Pharmaceuticals Co's value of 86.60% is 78.7% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #32 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #32 out of 935 companies for Gross Margin %. This places Jiangsu Hengrui Pharmaceuticals Co in the top 3% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.46. Jiangsu Hengrui Pharmaceuticals Co's value of 86.60% is 78.7% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Gross Margin % has ranged from 83.61 to 87.93 over the past decade. While the company's 10-year median is 86.43 vs. the industry median of 48.46, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Gross Margin % of 86.60% is 78.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Gross Margin % is 86.60%, which is near median its own 10-year median of 86.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.54, compared to a current price of ¥54.45 — trading 10.1% below its estimated fair value. The current Gross Margin % is 86.60%, which is near median its 10-year median of 86.43 and 78.7% above the Drug Manufacturers industry median of 48.46. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Gross Margin % is 86.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥54.45 is trading 10.1% below its estimated GF Value™ of ¥60.54.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
Gross Margin %: 86.60% (near median its 10-year median of 86.43)
GF Value™: ¥60.54 vs. price of ¥54.45 (10.1% below fair value)
Industry Position: 78.7% above the Drug Manufacturers median (#32 of 935)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
91GF Score
Get the complete analysis for SHSE:600276
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
